Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows from Operating Activities
Net loss	$ (4,082)	$ (1,623)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible asset	120	120
Amortization of vendor advances	1,958
Amortization of debt discount		154
Fair value of vested restricted stock units	223	5
Fair value of common shares issued in connection with the conversion of accounts payable		537
Fair value of warrants issued in connection with convertible notes payable		29
Changes in operating assets and liabilities:
Vendor advances		(1,515)
Prepaid expenses and other current assets	14	(2)
Accounts payable and accrued expenses	(590)	143
Net cash used in operating activities	(2,357)	(2,152)
Cash Flows from Financing Activities
Proceeds from the sale and exercise of prefunded warrants	3,058
Proceeds from the equity line of credit	3,602
Proceeds from common stock issued for cash in connection with the closing of the initial public offering		5,524
Proceeds from notes payable - officers		142
Payment of deferred offering costs		(390)
Net cash provided by financing activities	6,660	5,276
Net increase in cash and cash equivalents	4,303	3,124
Cash and cash equivalents, beginning of period	1,272	93
Cash and cash equivalents, end of period	5,575	3,217
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Common shares issued for deferred offering costs	327
Common shares issued for vendor advance	157
Reclassification of deferred offering costs to shareholders’ equity	397	872
Conversion of convertible notes payable and accrued interest to shareholders’ equity		884
Conversion of accounts payable to shareholders’ equity		1,014
Conversion of amounts due to related parties to shareholders’ equity		$ 4